SCHEDULE 13G: Adage Capital Management Discloses 6.84% Stake in Zevra Therapeutics
Beneficial Ownership Report
Adage Capital Management, L.P., along with its managing members Robert Atchinson and Phillip Gross, has disclosed a beneficial ownership of 6.84% in Zevra Therapeutics, Inc., totaling 3,650,000 shares of common stock.
Summary
- Adage Capital Management, L.P., a Delaware limited partnership, is filing this Schedule 13G as an investment manager.
- Robert Atchinson and Phillip Gross, both U.S. citizens, are also reporting persons as managing members of entities related to Adage Capital Management.
- The reporting persons collectively beneficially own 3,650,000 shares of Zevra Therapeutics, Inc. Common Stock.
- This ownership represents 6.84% of the total class of Zevra Therapeutics' common stock.
- The percentage is calculated based on 53,375,932 shares of Common Stock outstanding as of November 8, 2024, as reported in Zevra Therapeutics' Form 10-Q for the quarter ended September 30, 2024.
- The shares are held with shared voting power and shared dispositive power.
- The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 6
Explanation: The disclosure of a significant stake by a reputable institutional investor like Adage Capital Management is generally viewed as a positive signal, indicating confidence in the company. However, as a passive filing, it does not provide direct operational or financial performance insights, hence a moderately positive score.
Positives
- A significant stake by an institutional investor like Adage Capital Management can signal confidence in Zevra Therapeutics' future prospects.
- The filing indicates that the investment is for ordinary course of business, not for control, suggesting a passive investment strategy.
Negatives
- NA
Risks
- NA
Future Outlook
This Schedule 13G filing does not contain forward-looking statements or guidance from Zevra Therapeutics, Inc. It solely reports a change in beneficial ownership by an institutional investor.
Industry Context
This filing indicates a notable institutional investment in Zevra Therapeutics, a company operating in the biotechnology or pharmaceutical sector. Such investments are common as institutional funds seek to gain exposure to specific industries or companies they believe have growth potential. The disclosure of a significant stake by a reputable investment manager like Adage Capital Management can sometimes be viewed positively by the market, suggesting a vote of confidence in the company's prospects within its industry.
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional stake may increase investor confidence and potentially influence stock price positively due to perceived validation of the company's value.
- Company Management: Awareness of a large institutional holder may influence strategic decisions, though the filing states the stake is not for control purposes.
Key Dates
| Date | Description |
|---|---|
| 2024-09-30 | End of quarterly period for Zevra Therapeutics' Form 10-Q, which reported outstanding shares. |
| 2024-11-08 | Date as of which 53,375,932 shares of Common Stock were reported outstanding by Zevra Therapeutics. |
| 2024-11-13 | Date Zevra Therapeutics filed its Quarterly Report on Form 10-Q for the period ended September 30, 2024. |
| 2024-12-31 | Date of event which requires the filing of this Schedule 13G statement. |
| 2025-02-12 | Date of filing of this Schedule 13G statement. |
Keywords
Zevra Therapeutics, Adage Capital Management, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Equity Stake, SEC Filing, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.